10x Genomics: A Calculated Loss for a Strategic Leap Forward

PLEASANTON, CA – August 06, 2026 – At first glance, 10x Genomics' second-quarter earnings report tells a story of reversal. The life science technology leader posted a net loss of $17.9 million, a stark contrast to the $34.5 million in net income from the same period last year. Yet, in a move that signals deep confidence, the company simultaneously raised its full-year revenue guidance. This apparent contradiction is the key to understanding the firm's current strategy: a deliberate focus on long-term operational innovation, even at the cost of short-term financial optics. By looking past the headline numbers, a clearer picture emerges of a company methodically building its next phase of growth through strategic acquisitions, pivotal collaborations, and the launch of a potentially game-changing new product.

Deconstructing the Bottom Line

The swing from profit to loss is almost entirely an accounting story, rooted in the volatile world of patent litigation. Last year, 10x Genomics' Q2 results were significantly inflated by a major settlement, which added $27.3 million in non-recurring license and royalty revenue and a $40.7 million gain on settlement to the books. In contrast, this year's second quarter included a comparatively modest $1.6 million in settlement revenue.

When these distorting, non-recurring items are stripped away, the company’s core operational health becomes evident. Product and services revenue, the true measure of the underlying business, grew a steady 3% year-over-year to $149.4 million. This growth was driven by a robust 7% increase in consumables sales, indicating that the existing base of installed instruments is being used more intensively—a crucial metric for the company's razor-and-blade business model. Single-cell reaction volumes, a key performance indicator, showed double-digit growth.

Further evidence of operational strength can be found in the company's margins. Gross margin improved to 74% from 72% a year ago, a gain attributed to lower manufacturing costs and $2.6 million in tariff refunds. When adjusted for the settlement noise, the improvement is even more pronounced, jumping from 67% to 74%. Moreover, while reported operating expenses surged 39%, they were approximately flat year-over-year when excluding the settlement gains from both periods. This demonstrates disciplined cost management, even as the company invests heavily in its future.

Atera's Triumph and the Product Pipeline

The most significant forward-looking indicator in the report came directly from Co-founder and CEO Serge Saxonov. "The story of the quarter was the extraordinary customer response to Atera," he stated in the press release. Atera, the company's highly anticipated new instrument platform, appears to be a resounding success even before its first shipments.

The company reported that booked orders for the new system are already "well above the approximately 40 instruments" it has the manufacturing capacity to ship in 2026. This overwhelming demand, spanning academia, medical centers, and biopharma, suggests Atera addresses a critical unmet need in the single-cell and spatial biology markets. Analysts noted that the potential utilization rate for Atera is estimated to be roughly twice that of Xenium, another of the company's successful spatial biology platforms, pointing to a significant future revenue stream from high-margin consumables.

This early triumph is creating a classic 'good problem' for the company. The excitement around Atera led some customers to defer purchases of existing Xenium and Visium instruments, causing a 47% decline in total instrument revenue for the quarter. While this creates a temporary dip, it is a strong validation of the new platform's appeal. The operational challenge now shifts to scaling manufacturing to meet the backlog of orders, a move that will unlock substantial revenue growth in late 2026 and beyond.

Building a Multiomics and Diagnostics Powerhouse

Beyond the Atera launch, 10x Genomics executed two major strategic initiatives this quarter that reveal its ambition to move beyond its core research tools market. The first was the acquisition of Proteintech Genomics, a division of Proteintech Group. This move is a direct play to dominate the burgeoning field of multiomics, which integrates multiple layers of biological data—like genomics, transcriptomics, and proteomics—to create a more complete picture of cellular function. By incorporating Proteintech's advanced protein detection capabilities, 10x Genomics can offer researchers a more holistic solution on a single platform, strengthening its competitive moat.

The second major initiative involves new multi-year research collaborations with two world-class institutions: Cleveland Clinic and Lausanne University Hospital. The explicit goal is to advance the use of single-cell and spatial technologies in diagnostic applications for cancer care. This represents a significant step in the company's long-term strategy to bridge the gap between the research lab and the clinic. By partnering with leading medical centers, 10x Genomics gains access to invaluable clinical expertise, patient samples, and a direct pathway to validate its technology for diagnostic use. Success in these collaborations could open up the vast and lucrative clinical diagnostics market, transforming the company's growth trajectory.

Navigating a Competitive and Evolving Market

These strategic maneuvers are positioning 10x Genomics to capitalize on powerful tailwinds in the life sciences industry, including the increasing use of artificial intelligence in biological research, which demands the kind of high-quality, high-resolution data its platforms produce. The raised full-year revenue guidance, now set at $610 million to $630 million (representing 2% to 5% core growth), underscores management's confidence in its strategy despite the competitive landscape that includes heavyweights like Illumina and specialized players like NanoString Technologies.

Investors and analysts appear to be looking through the short-term noise, focusing on the strong Atera order book and the long-term potential of the company's strategic pivots. With a healthy balance sheet showing $552 million in cash and marketable securities, 10x Genomics has the financial firepower to continue investing in R&D and strategic initiatives. The company is making a clear and calculated trade-off, accepting temporary complexity in its financial reporting in exchange for building a more dominant and defensible market position for the years to come.